# CPI-006

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/cpi-006
Canonical HTML page: https://gethealthbrief.com/entity/cpi-006

## Timeline

- **2026-08-07**: Q2 2026 Earnings Release — Company reported EPS of ($0.19), missing consensus by $0.03.
- **2026-07-30**: Ladenburg Thalmann Upgrade — Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.
- **2026-07-28**: Weiss Ratings Upgrade — Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.
- **2026-06-11**: Director Insider Purchase — Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.
- **2026-05-09**: Wall Street Zen Downgrade — Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.
- **2026-04-17**: Goldman Sachs Initiates Coverage — Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.

## Recent coverage (1 stories)

### Corvus Pharma miss $0.03 EPS as pipeline awaits clinical catalysts
2026-08-12 14:39:50 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Corvus Pharmaceuticals missed Q2 EPS by $0.03, highlighting the financial fragility of early-stage oncology R&D. With no near-term data readouts, the miss draws attention to cash burn and the critical need for clinical progress to justify its $1.17B valuation.
Full story: https://gethealthbrief.com/story/corvus-earnings-miss-healthcare-implications

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.